CLINICAL_TRIALS
trial_result
· 2023-12-12
Clinical Trial Update: Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure [Phase 2]
Summary
Phase 2 trial assessing dapagliflozin effect on submaximal exercise tolerance in heart failure with reduced ejection fraction (HFrEF) has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Pennsylvania | Conditions: HFrEF | Phase 2 | Status: COMPLETED